# LianBio: overview LIANY · OTC · CIK 1831283 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/liany.md) · [Financials](/companies/liany/financials.md) · [Filings](/companies/liany/filings.md) · [Insiders](/companies/liany/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(0.26)](/filings/0001831283-23-000081.md) | [(0.39)](/filings/0001831283-23-000110.md) | [(0.20)](/filings/0001831283-23-000126.md) | not reported | [(0.22)](/filings/0001831283-23-000081.md) | [(0.20)](/filings/0001831283-23-000110.md) | [(0.22)](/filings/0001831283-23-000126.md) | | Free cash flow | $m | [(31.2) d](/filings/0001831283-23-000041.md) | [(13.4)](/filings/0001831283-23-000081.md) | [(39.7) d](/filings/0001831283-23-000110.md) | [(16.9) d](/filings/0001831283-23-000126.md) | [(30.9) d](/filings/0001831283-23-000041.md) | [(17.7)](/filings/0001831283-23-000081.md) | [(19.4) d](/filings/0001831283-23-000110.md) | [(16.0) d](/filings/0001831283-23-000126.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY (2020-12-31) | FY2021 (2021-12-31) | FY2022 (2022-12-31) | | --- | --- | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | | Diluted EPS | $ per share | [(11.58)](/filings/0001831283-22-000014.md) | [(5.71)](/filings/0001831283-23-000041.md) | [(1.02)](/filings/0001831283-23-000041.md) | | Free cash flow | $m | [(99.0)](/filings/0001831283-22-000014.md) | [(165)](/filings/0001831283-23-000041.md) | [(101)](/filings/0001831283-23-000041.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/liany/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [FNY Investment Advisers, LLC](/funds/1742998.md) | 2026-06-30 | $1 | 14,000 | | Unchanged | ## Recent filings [All 170 filings](/companies/liany/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2024-02-29 | 19:45 ET | [SC 13D/A](/filings/0001193125-24-053902.md) | Ownership report, active investor, amended | 0001193125-24-053902 | | 2024-02-13 | 07:04 ET | [8-K](/filings/0001831283-24-000004.md) | 2.05 Exit or disposal costs; 3.01 Delisting notice; 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001831283-24-000004 | | 2023-12-26 | 16:07 ET | [8-K](/filings/0001831283-23-000145.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement | 0001831283-23-000145 | | 2023-12-20 | 08:05 ET | [8-K](/filings/0001831283-23-000141.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001831283-23-000141 | | 2023-12-19 | 16:26 ET | [8-K](/filings/0001831283-23-000137.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001831283-23-000137 | | 2023-12-06 | 16:23 ET | [8-K](/filings/0001831283-23-000133.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001831283-23-000133 | | 2023-12-01 | 16:16 ET | [8-K](/filings/0001831283-23-000129.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001831283-23-000129 | | 2023-11-30 | 17:08 ET | [SC 13D](/filings/0001214659-23-015813.md) | Ownership report, active investor | 0001214659-23-015813 | | 2023-11-13 | 16:28 ET | [10-Q](/filings/0001831283-23-000126.md) | Quarterly report, period 2023-09-30 | 0001831283-23-000126 | | 2023-11-13 | 16:17 ET | [8-K](/filings/0001831283-23-000124.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001831283-23-000124 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2022](/filings/0001831283-23-000041.md), filed Mar 28, 2023. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1831283 - Tickers: LIANY - Exchange: OTC - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: E9 - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:48 ET. No prices; not investment advice.